Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review

Key Points

• Immune-mediated liver injury from checkpoint inhibitors is a growing concern in oncology, impacting patient management strategies.
• The review outlines the pathogenesis and clinical approach to immune-mediated liver injury, highlighting varied manifestations, from mild cases to severe liver failure.
• Narrative literature review provides an overview of the risks associated with immune checkpoint inhibitors, indicating potential for significant adverse events in cancer therapy.
• Understanding immune-mediated liver injury can enhance clinical decision-making during immunotherapy, supporting better patient outcomes.